Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
https://www.zacks.com/stock/news/2315373/alnylam-alny-up-as-q2-earnings-beat-on-collaboration-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2315373
Aug 02, 2024 - Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.
0
Koninklijke BAM Groep nv (KBAGF) Q2 2024 Earnings Call Transcript
https://seekingalpha.com/article/4707449-koninklijke-bam-groep-nv-kbagf-q2-2024-earnings-call-transcript?source=feed_sector_transcripts
Jul 27, 2024 - Koninklijke BAM Groep nv (OTCPK:KBAGF) Q2 2024 Earnings Call Transcript July 25, 2024 4:00 AM ETCompany ParticipantsMichel Aupers - IR ManagerRuud Joosten -...
0
NV Bekaert SA (BEKSF) Q2 2024 Earnings Call Transcript
https://seekingalpha.com/article/4707331-nv-bekaert-sa-beksf-q2-2024-earnings-call-transcript?source=feed_sector_transcripts
Jul 26, 2024 - NV Bekaert SA (OTCPK:BEKSF) Q2 2024 Results Conference Call July 24, 2024 4:00 AM ETCompany ParticipantsGuy Marks - Investor RelationsYves Kerstens - Chief...
0
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
https://www.zacks.com/stock/news/2305396/ionis-ions-completes-enrolment-for-rare-disease-drug-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2305396
Jul 19, 2024 - Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
0
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/07/18/novartis-ag-nvs-q2-2024-earnings-call-transcript/?source=iedfolrf0000001
Jul 18, 2024 - NVS earnings call for the period ending June 30, 2024.
0
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
https://www.zacks.com/stock/news/2293892/fda-accepts-ionis-ions-nda-for-rare-disease-drug-olezarsen?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2293892
Jun 26, 2024 - The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
0
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
https://www.zacks.com/stock/news/2290616/ionis-ions-expands-licensing-deal-with-otsuka-for-hae-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290616
Jun 19, 2024 - Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
0
Why Novartis (NVS) is a Top Value Stock for the Long-Term
https://www.zacks.com/stock/news/2284645/why-novartis-nvs-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2284645
Jun 06, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2283315/why-novartis-nvs-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2283315
Jun 04, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript)
https://seekingalpha.com/article/4697234-novartis-ag-nvs-investor-event-asco-conference-call-transcript?source=feed_sector_transcripts
Jun 03, 2024 -
0